August 15, 2016

All Trials

ANEMIA

Check back soon for upcoming trials.

BREAST CANCER

An open-label randomized phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies

A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy

CERVICAL CANCER

Check back soon for upcoming trials.

CINV (CHEMOTHERAPY INDUCED NAUSEA AND VOMITING)

Check back soon for upcoming trials.

COLON CANCER

A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)

ESOPHAGEAL CANCER

Check back soon for upcoming trials.

GASTRIC CANCER

Check back soon for upcoming trials.

HEAD AND NECK CANCER

Check back soon for upcoming trials.

ITP (IDIOPATHIC THROMBOCYTOPENIC PURPURA)

Check back soon for upcoming trials.

LEUKEMIA

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

Phase 1B study of PTC299 in relapsed/refactory acute leukemias

A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies

A Phase 1 first-in human, multi-center, open label dose-escalation study to determine the safety ,tolerablilty pharmacokinetics and RP2D of Abbv-184 as a single agent in subjects with previoulsy treated cancers

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination inTreatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

A Phase IB/II study of APG-2575 as a single agent or in combination with other therapeutics agents in patients  with relapsed and/or refactory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) (SACRED)

A Phase 1B study of the pharmacokinetics, safety and efficacy or orally administered HQP1351 in subjects with  refactory chronic myeloid leukemia (CML)

LIVER CANCER

Check back soon for upcoming trials.

LUNG

A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety between TRS003 and China-approved Bevacizumab Administered in Combination with Paclitaxel-Carboplatin in Subjects with Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC)

A PHASE 1 FIRST-IN HUMAN, MULTI-CENTER, OPEN LABEL DOSE-ESCALATION STUDY TO DETERMINE THE SAFETY, TOLERABILITY PHARMACOKINETICS AND RP2D OF ABBV-184 AS A SINGLE AGENT IN SUBJECTS WITH PREVIOUSLY TREATED CANCERS

LYMPHOMA

MDS (MYELODYSPLASTIC SNYDROME)

A phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell Transfusion (RBC) Transfusion Burden (LTB)

MELANOMA

An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents CoAdministered with Encorafenib and Binimetinib in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

MULTIPLE MYELOMA

Check back soon for upcoming trials.

MYELOFIBROSIS

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

NEUROENDOCRINE

Check back soon for upcoming trials.

OVARIAN

Check back soon for upcoming trials.

PAIN MANAGEMENT

Check back soon for upcoming trials.

PANCREATIC CANCER

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects

POLYCYTHEMIA VERA

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera

PROSTATE CANCER

A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU111 in Men with Advanced Metastatic Castration Resistant Prostate Cancer

RENAL CELL / KIDNEY CANCER

Check back soon for upcoming trials.

SOLID TUMOR

An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies

A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas

An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents CoAdministered with Encorafenib and Binimetinib in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

A Phase 1, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

A PHASE 2, MULTICENTER, OPEN-LABEL, MULTI-COHORT STUDY TO ASSESS SAFETY AND EFFICACY OF CC-90011 IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH ADVANCED CANCERS

A PHASE I, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADYSTATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES

A PHASE 1, OPEN-LABEL MULTI-DOSE PHARMCOKINETIC AND SAFETY STUDY OF ORAL TAZEMETOSTAT IN SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT WITH ADVANCED MALIGNANCIES

An open-label, multi-center, phase 1b/2 study to evaluate the safety and efficacy of copanlisib in combination with nivolumab in patients with advanced solid tumors 

 UROTHELIAL CANCER  

A STUDY OF ENFORTUMAB VEDOTIN (ASG-22CE) AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER

WALDENSTROM’S MACROGLOBULINEMIA

Check back soon for upcoming trials.